This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baidas, S. M. Articles by Hayes, D. F. Search for Related Content PubMed PubMed Citation Articles by Baidas, S. M. Articles by Hayes, D. F. Social Bookmarking                            What's this?

Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer

From the Breast Cancer and Development Therapeutic Programs, Lombardi Cancer Center, Georgetown University Medical Center, Georgetown University, Washington, DC; Dana-Farber Cancer Institute, Boston, MA; University of Chicago Medical Center, Chicago, IL; Duke University Medical Center, Durham, NC; and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.

Address reprint requests to Said Baidas, MD, Georgetown University Medical Center, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007; email Baidass{at}gunet.georgetown.edu

PURPOSE: To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer.

PATIENTS AND METHODS: Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 200 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pretreated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated.

RESULTS: No patient had a true partial or complete response. On the 800-mg arm, 13 patients had progressive disease at or before 8 weeks of treatment and one refused to continue treatment. The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for two and was increased for one to 1,000 mg and for four to 1,200 mg. On the 200-mg arm, 12 patients had progressive disease at or before 8 weeks and two had stable disease at 8 weeks, of whom one was removed from study at week 11 because of grade 3 neuropathy and the other had progressive disease at week 16. Dose-limiting toxicities included somnolence and neuropathy. Adverse events that did not require dose or schedule modifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia. Evaluation of circulating angiogenic factors and pharmacokinetic studies failed to provide insight into the reason for the lack of efficacy.

CONCLUSION: Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer. Further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]

				M. Colleoni, L. Orlando, G. Sanna, A. Rocca, P. Maisonneuve, G. Peruzzotti, R. Ghisini, M. T. Sandri, L. Zorzino, F. Nole, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Ann. Onc., February 1, 2006; 17(2): 232 - 238. [Abstract] [Full Text] [PDF]

				V. Eleutherakis-Papaiakovou, A. Bamias, and M. A. Dimopoulos Thalidomide in cancer medicine Ann. Onc., August 1, 2004; 15(8): 1151 - 1160. [Abstract] [Full Text] [PDF]

				S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF]

				M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]

				S. Zhou Correspondence re: J. Lu et al., Thalidomide Metabolites in Mice and Patients with Multiple Myeloma. Clin. Cancer Res., 9: 1680-1688, 2003. Clin. Cancer Res., November 1, 2003; 9(14): 5429 - 5429. [Full Text] [PDF]

				C.-K. Lee, B. Barlogie, N. Munshi, M. Zangari, A. Fassas, J. Jacobson, F. van Rhee, M. Cottler-Fox, F. Muwalla, and G. Tricot DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma J. Clin. Oncol., July 15, 2003; 21(14): 2732 - 2739. [Abstract] [Full Text] [PDF]

				F.-C. Lee ; and M. Zangari Second response to lower-dose thalidomide in a patient with multiple myeloma Blood, May 13, 2002; 99(11): 4248 - 4249. [Full Text] [PDF]

				M. B. Steins, T. Padro, R. Bieker, S. Ruiz, M. Kropff, J. Kienast, T. Kessler, T. Buechner, W. E. Berdel, and R. M. Mesters Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood, February 1, 2002; 99(3): 834 - 839. [Abstract] [Full Text] [PDF]

				A. Onn, J. E. Tseng, and R. S. Herbst Thalidomide, Cyclooxygenase-2, and Angiogenesis: Potential for Therapy Clin. Cancer Res., November 1, 2001; 7(11): 3311 - 3313. [Full Text] [PDF]